Oncternal Therapeutics

OverviewSuggest Edit

Oncternal Therapeutics is a clinical-stage oncology company developing first-in-class and novel therapies for both rare and common cancers. Our pipeline has recently expanded and now includes two clinical-stage products with common regulatory and development strategies.
Our cutting-edge scientific approach is focused on targets that are uniquely expressed within cancer cells, resulting in highly targeted new therapies. We also apply a variety of therapeutic strategies to address different medical challenges - from antibodies and antibody-drug conjugates (ADCs) to small molecules and chimeric antigen receptor T-cells (CAR-T).
By leveraging our strong scientific and development skills, as well as academic collaborations, we are working to rapidly advance our two clinical-stage pipeline products, cirmtuzumab and TK216. Both cirmtuzumab and TK216 are being developed for various tumor types, including some of the most devastating and underserved forms of cancer.

TypePrivate
Founded2013
HQSan Diego, CA, US
Websiteoncternal.com

Latest Updates

Cybersecurity ratingAMore

Key People/Management at Oncternal Therapeutics

Jim Breitmeyer

Jim Breitmeyer

CEO
Dana McGowan

Dana McGowan

CFO
Langdon Miller

Langdon Miller

Chief Medical Officer
Brian Lannutti

Brian Lannutti

CSO
Lauren Otsuki

Lauren Otsuki

Chief Business Officer
Show more

Oncternal Therapeutics Office Locations

Oncternal Therapeutics has an office in San Diego
San Diego, CA, US (HQ)
12230 El Camino Real #300
Show all (1)

Oncternal Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2013

Oncternal Therapeutics total Funding

$18.6 m

Oncternal Therapeutics latest funding size

$18.40 m

Time since last funding

4 years ago
Oncternal Therapeutics's latest funding round in February 2017 was reported to be $18.4 m. In total, Oncternal Therapeutics has raised $18.6 m
Show all financial metrics

Oncternal Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Oncternal Therapeutics Online and Social Media Presence

Embed Graph

Oncternal Therapeutics News and Updates

Oncternal Therapeutics, Inc. Confirms Lentigen Technology, Inc. to Manufacture Lentiviral Vectors for Its ROR1-targeting CAR-T Cell Therapy Program

SAN DIEGO, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced an agreement with Lentigen Technology, Inc. (“Lentigen”), a wholly-owned subsidiary of Milten…

Oncternal Therapeutics and Karolinska Institutet Establish Collaboration for Research and Development of ROR1-targeting CAR-T and CAR-NK Cell Therapies

SAN DIEGO and STOCKHOLM, Sweden, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it established a research and development collaboration with world…

Oncternal Therapeutics Announces $40.0 Million Bought Deal Offering

SAN DIEGO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under …

Oncternal Therapeutics Announces Presentation of Interim Phase 1/2 Data Update for Cirmtuzumab in Combination with Ibrutinib at ASH 2020 Virtual Annual Meeting

SAN DIEGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced updated interim clinical data from the ongoing Phase 1/2 CIRLL (Cirmtuzumab and Ibrutinib tar…

Oncternal Therapeutics Announces $20.0 Million Bought Deal Offering

SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under …

Oncternal Therapeutics Completes Reverse Merger with GTx, Inc.

Shares of Oncternal to commence trading on Nasdaq under new ticker symbol ONCT on June 10, 2019 Shares of Oncternal to commence trading on Nasdaq under new ticker symbol ONCT on June 10, 2019

Oncternal Therapeutics Frequently Asked Questions

  • When was Oncternal Therapeutics founded?

    Oncternal Therapeutics was founded in 2013.

  • Who are Oncternal Therapeutics key executives?

    Oncternal Therapeutics's key executives are Jim Breitmeyer, Dana McGowan and Langdon Miller.

  • Who are Oncternal Therapeutics competitors?

    Competitors of Oncternal Therapeutics include Aptevo Therapeutics, Aeglea Biotherapeutics and Cleveland BioLabs.

  • Where is Oncternal Therapeutics headquarters?

    Oncternal Therapeutics headquarters is located at 12230 El Camino Real #300, San Diego.

  • Where are Oncternal Therapeutics offices?

    Oncternal Therapeutics has an office in San Diego.

  • How many offices does Oncternal Therapeutics have?

    Oncternal Therapeutics has 1 office.